Prednisolone Sodium Phosphate

Concomitant use increases risk of gastrointestinal side effects; use cautiously in hypoprothrombinemia.

Aminoglutethimide may lead to loss of corticosteroid-induced adrenal suppression.

Concomitant use may result in cardiac enlargement and congestive heart failure, particularly due to potassium depletion.

Concurrent use may produce severe weakness in patients with myasthenia gravis; anticholinesterase agents should be withdrawn 24 hours before initiating corticosteroids if possible.

CYP 3A4 inducers enhance metabolism of prednisolone, requiring increased dosage of corticosteroid.

CYP 3A4 inducer enhances metabolism of prednisolone, requiring increased dosage of corticosteroid.

Concurrent use increases activity of both cyclosporin and corticosteroids with convulsions reported.

Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia from concurrent corticosteroid use.

CYP 3A4 inducer enhances metabolism of prednisolone, requiring increased dosage of corticosteroid.

Ketoconazole decreases metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.

Corticosteroids may potentiate replication of organisms in live attenuated vaccines and suppress antibody response; routine vaccination should be deferred until therapy discontinued.

CYP 3A4 inhibitors that may decrease metabolism of corticosteroids, increasing risk of side effects.

CYP 3A4 inducer enhances metabolism of prednisolone, requiring increased dosage of corticosteroid.

CYP 3A4 inducer enhances metabolism of prednisolone, requiring increased dosage of corticosteroid.

Concomitant use increases gastrointestinal side effects; clearance of salicylates may be increased.

Corticosteroids may increase blood glucose concentrations, requiring dosage adjustments of antidiabetic agents.

Cholestyramine may increase the clearance of corticosteroids.

Potassium-depleting diuretics used with corticosteroids require close observation for hypokalemia development.

Estrogens decrease hepatic metabolism of certain corticosteroids, increasing their effect.

Prolonged corticosteroid therapy may diminish response to inactivated vaccines due to inhibition of antibody response.

Serum concentrations of isoniazid may be decreased by corticosteroid co-administration.

Concomitant use with NSAIDs increases the risk of gastrointestinal side effects.

Oral contraceptives may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Prolonged corticosteroid therapy may diminish response to toxoids due to inhibition of antibody response; routine administration should be deferred if possible.

Corticosteroids may diminish response to live or inactivated vaccines and potentiate replication of organisms in live attenuated vaccines.

Corticosteroids usually inhibit response to warfarin; coagulation indices should be monitored frequently to maintain anticoagulant effect.

Drug Interactions Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Prednisolone Sodium Phosphate Oral Solution (15 mg Prednisolone per 5 mL) be increased.